Umer Masood, Mohib Yasir, Atif Muhammed, Nazim Muhammad
Aga Khan University Hospital Karachi, Pakistan.
Ann Med Surg (Lond). 2018 Jan 31;27:9-16. doi: 10.1016/j.amsu.2018.01.002. eCollection 2018 Mar.
Renal cell carcinoma account for 3% of all cancers, with peak incidence between 60 and 70 years of age predominantly affecting male population. Renal carcinoma is the most common malignancy of kidney constitutes for 80-90% of renal neoplasm with an overall 45% five years survival rate. Majority are diagnosed incidentally during investigation for other disease process of abdomen. Classical triad of gross hematuria, pain and palpable mass in abdomen is rare accounting to only 6-10%. Treatment of early stages of disease i.e. localized disease is partial or radical nephrectomy. Most common metastasis in RCC occurs to lung, followed by bone involvement in 20-35%, lymph nodes, liver, adrenal gland and brain. In metastatic disease median survival rate of patient is about eight months with 50% mortality rate within first year of life, five years survival rate is 10%. Skeletal metastasis are very destructive in patients with renal cell carcinoma compromising bone integrity leading to skeletal related events including pains, impending fractures, nerve compressions, hypercalcemia and even pathological fractures which may require surgical interventions and other therapy. In addition to skeletal complications, presence of bone metastases in RCC has negative impact on progression free survival and overall survival of patients treated with systemic therapies.
In this review we discuss pathophysiology of tumor metastasis, diagnosis, management and Case examples of metastatic renal cell carcinoma.
Incidence of metastatic renal carcinoma is increasing. Overall prognosis of patient with advanced RCC is poor, emphasizing the importance of early detection and prompt treatment of primary lesion in its early stage. Advancement in targeted therapy in recent decades had made some improvement in treatment of SREs and has helped in improving patent's quality of life but still we are in need of further improvement in treatment modalities to cure disease thereby decreasing morbidity and mortality.
肾细胞癌占所有癌症的3%,发病高峰在60至70岁之间,主要影响男性人群。肾癌是肾脏最常见的恶性肿瘤,占肾肿瘤的80 - 90%,总体五年生存率为45%。大多数是在对腹部其他疾病进行检查时偶然发现的。典型的肉眼血尿、疼痛和腹部可触及肿块三联征很少见,仅占6 - 10%。疾病早期即局限性疾病的治疗是部分或根治性肾切除术。肾细胞癌最常见的转移部位是肺,其次是骨转移,发生率为20 - 35%,还可转移至淋巴结、肝脏、肾上腺和脑。在转移性疾病中,患者的中位生存率约为8个月,第一年死亡率为50%,五年生存率为10%。骨转移对肾细胞癌患者具有极大的破坏性,损害骨完整性,导致骨骼相关事件,包括疼痛、即将发生的骨折、神经压迫、高钙血症,甚至病理性骨折,这可能需要手术干预和其他治疗。除了骨骼并发症外,肾细胞癌骨转移的存在对接受全身治疗患者的无进展生存期和总生存期有负面影响。
在本综述中,我们讨论肿瘤转移的病理生理学、转移性肾细胞癌的诊断、管理及病例实例。
转移性肾癌的发病率正在上升。晚期肾细胞癌患者的总体预后较差,强调早期发现和及时治疗原发性病变早期阶段的重要性。近几十年来靶向治疗的进展在治疗骨相关事件方面取得了一些进展,并有助于改善患者的生活质量,但我们仍需要进一步改进治疗方式以治愈疾病,从而降低发病率和死亡率。